Skip to content

Development of Multi-omics Assisted Early Diagnostic Technology for Cervical Cancer

Development of Multi-omics Assisted Early Diagnostic Technology for Cervical Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119270
Enrollment
Unknown
Registered
2026-02-25
Start date
2026-03-07
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Gold Standard:Histopathological results from colposcopy and subsequent excisional therapy serve as the gold standard for the diagnosis of cervical cancer and precancerous lesions
Index test:Multi-omics biomarker panel

Sponsors

China Welfare association international peace Maternal and Child Health hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Females aged 25 years or older, with a history of sexual activity and not currently pregnant; 2.Intact cervix; 3.No history of CIN treatment within the past 6 months; 4.No history of malignant tumors; 5.Able and willing to provide all three types of tissue samples in accordance with the study protocol, ensuring cervical tissue sample >=10mg, cervical exfoliated cell sample >=3ml, and peripheral blood sample >=5ml. 6.Voluntarily participate in this study, be able to understand the study procedures, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating women; 2.Prior history of cancer in any organ; 3.Have severe uncontrolled systemic disease (e.g., heart, lung, liver, or kidney failure; active autoimmune disease). 4.Incomplete medical record information (including but not limited to sex, age, clinicopathological diagnosis, and other demographic data) or incomplete sample identification that prevents accurate matching. 5.Prior history of CIN2, CIN3, or cervical carcinoma, along with any associated treatment (e.g., surgery); 6.Withdrew prematurely from the study before reaching the endpoint; 7.Exclusion due to: insufficient sample volume, poor sample quality, or technical failure in assay data generation for any sample type;

Design outcomes

Primary

MeasureTime frame
Multi-omics biomarker panel;

Secondary

MeasureTime frame
Pathology report of cervical biopsy after colposcopy;

Countries

China

Contacts

Public ContactYudong Wang

China Welfare association international peace Maternal and Child Health hospital

owangyudong@126.com+86 21 64070434

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026